1 Report Overview

• 1.1 Study Scope
• 1.2 Key Market Segments
• 1.3 Players Covered: Ranking by Gene Therapy for CNS Disorders Revenue
• 1.4 Market Analysis by Type
  • 1.4.1 Global Gene Therapy for CNS Disorders Market Size Growth Rate by Type: 2020 VS 2026
  • 1.4.2 Ex Vivo
  • 1.4.3 In Vivo
• 1.5 Market by Application
  • 1.5.1 Global Gene Therapy for CNS Disorders Market Share by Application: 2020 VS 2026
  • 1.5.2 Hospitals
  • 1.5.3 Clinics
  • 1.5.4 Others
• 1.6 Coronavirus Disease 2019 (Covid-19): Gene Therapy for CNS Disorders Industry Impact
  • 1.6.1 How the Covid-19 is Affecting the Gene Therapy for CNS Disorders Industry
    • 1.6.1.1 Gene Therapy for CNS Disorders Business Impact Assessment - Covid-19
    • 1.6.1.2 Supply Chain Challenges
    • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
  • 1.6.2 Market Trends and Gene Therapy for CNS Disorders Potential Opportunities in the COVID-19 Landscape
  • 1.6.3 Measures / Proposal against Covid-19
    • 1.6.3.1 Government Measures to Combat Covid-19 Impact
    • 1.6.3.2 Proposal for Gene Therapy for CNS Disorders Players to Combat Covid-19 Impact
• 1.7 Study Objectives
• 1.8 Years Considered

2 Global Growth Trends by Regions

• 2.1 Gene Therapy for CNS Disorders Market Perspective (2015-2026)
• 2.2 Gene Therapy for CNS Disorders Growth Trends by Regions
  • 2.2.1 Gene Therapy for CNS Disorders Market Size by Regions: 2015 VS 2020 VS 2026
  • 2.2.2 Gene Therapy for CNS Disorders Historic Market Share by Regions (2015-2020)
  • 2.2.3 Gene Therapy for CNS Disorders Forecasted Market Size by Regions (2021-2026)
• 2.3 Industry Trends and Growth Strategy
  • 2.3.1 Market Top Trends
  • 2.3.2 Market Drivers
  • 2.3.3 Market Challenges
  • 2.3.4 Porter’s Five Forces Analysis
  • 2.3.5 Gene Therapy for CNS Disorders Market Growth Strategy
  • 2.3.6 Primary Interviews with Key Gene Therapy for CNS Disorders Players (Opinion Leaders)

3 Competition Landscape by Key Players

• 3.1 Global Top Gene Therapy for CNS Disorders Players by Market Size
  • 3.1.1 Global Top Gene Therapy for CNS Disorders Players by Revenue (2015-2020)
  • 3.1.2 Global Gene Therapy for CNS Disorders Revenue Market Share by Players (2015-2020)
  • 3.1.3 Global Gene Therapy for CNS Disorders Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
• 3.2 Global Gene Therapy for CNS Disorders Market Concentration Ratio
  • 3.2.1 Global Gene Therapy for CNS Disorders Market Concentration Ratio (CR5 and HHI)
  • 3.2.2 Global Top 10 and Top 5 Companies by Gene Therapy for CNS Disorders Revenue in 2019
• 3.3 Gene Therapy for CNS Disorders Key Players Head office and Area Served
• 3.4 Key Players Gene Therapy for CNS Disorders Product Solution and Service
• 3.5 Date of Enter into Gene Therapy for CNS Disorders Market
• 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

• 4.1 Global Gene Therapy for CNS Disorders Historic Market Size by Type (2015-2020)
• 4.2 Global Gene Therapy for CNS Disorders Forecasted Market Size by Type (2021-2026)

5 Gene Therapy for CNS Disorders Breakdown Data by Application (2015-2026)

• 5.1 Global Gene Therapy for CNS Disorders Market Size by Application (2015-2020)
• 5.2 Global Gene Therapy for CNS Disorders Forecasted Market Size by Application (2021-2026)

6 North America

• 6.1 North America Gene Therapy for CNS Disorders Market Size (2015-2020)
• 6.2 Gene Therapy for CNS Disorders Key Players in North America (2019-2020)
• 6.3 North America Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
• 6.4 North America Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

7 Europe

• 7.1 Europe Gene Therapy for CNS Disorders Market Size (2015-2020)
• 7.2 Gene Therapy for CNS Disorders Key Players in Europe (2019-2020)
• 7.3 Europe Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
• 7.4 Europe Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

8 China

• 8.1 China Gene Therapy for CNS Disorders Market Size (2015-2020)
• 8.2 Gene Therapy for CNS Disorders Key Players in China (2019-2020)
• 8.3 China Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
• 8.4 China Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

9 Japan

• 9.1 Japan Gene Therapy for CNS Disorders Market Size (2015-2020)
• 9.2 Gene Therapy for CNS Disorders Key Players in Japan (2019-2020)
• 9.3 Japan Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
• 9.4 Japan Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

10 Southeast Asia

• 10.1 Southeast Asia Gene Therapy for CNS Disorders Market Size (2015-2020)
• 10.2 Gene Therapy for CNS Disorders Key Players in Southeast Asia (2019-2020)
• 10.3 Southeast Asia Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
• 10.4 Southeast Asia Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

11 India

• 11.1 India Gene Therapy for CNS Disorders Market Size (2015-2020)
• 11.2 Gene Therapy for CNS Disorders Key Players in India (2019-2020)
• 11.3 India Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
• 11.4 India Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

12 Central & South America

• 12.1 Central & South America Gene Therapy for CNS Disorders Market Size (2015-2020)
• 12.2 Gene Therapy for CNS Disorders Key Players in Central & South America (2019-2020)
• 12.3 Central & South America Gene Therapy for CNS Disorders Market Size by Type (2015-2020)
• 12.4 Central & South America Gene Therapy for CNS Disorders Market Size by Application (2015-2020)

13 Key Players Profiles

• 13.1 Gilead (Kite Pharma)
  • 13.1.1 Gilead (Kite Pharma) Company Details
  • 13.1.2 Gilead (Kite Pharma) Business Overview and Its Total Revenue
  • 13.1.3 Gilead (Kite Pharma) Gene Therapy for CNS Disorders Introduction
  • 13.1.4 Gilead (Kite Pharma) Revenue in Gene Therapy for CNS Disorders Business (2015-2020))
  • 13.1.5 Gilead (Kite Pharma) Recent Development
• 13.2 Amgen (BioVex)
  • 13.2.1 Amgen (BioVex) Company Details
  • 13.2.2 Amgen (BioVex) Business Overview and Its Total Revenue
  • 13.2.3 Amgen (BioVex) Gene Therapy for CNS Disorders Introduction
  • 13.2.4 Amgen (BioVex) Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
  • 13.2.5 Amgen (BioVex) Recent Development
• 13.3 Novartis
  • 13.3.1 Novartis Company Details
  • 13.3.2 Novartis Business Overview and Its Total Revenue
  • 13.3.3 Novartis Gene Therapy for CNS Disorders Introduction
  • 13.3.4 Novartis Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
  • 13.3.5 Novartis Recent Development
• 13.4 Roche (Spark Therapeutics)
  • 13.4.1 Roche (Spark Therapeutics) Company Details
  • 13.4.2 Roche (Spark Therapeutics) Business Overview and Its Total Revenue
  • 13.4.3 Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Introduction
  • 13.4.4 Roche (Spark Therapeutics) Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
  • 13.4.5 Roche (Spark Therapeutics) Recent Development
• 13.5 Bluebird Bio
  • 13.5.1 Bluebird Bio Company Details
  • 13.5.2 Bluebird Bio Business Overview and Its Total Revenue
  • 13.5.3 Bluebird Bio Gene Therapy for CNS Disorders Introduction
  • 13.5.4 Bluebird Bio Revenue in Gene Therapy for CNS Disorders Business (2015-2020)
  • 13.5.5 Bluebird Bio Recent Development

14 Analyst's Viewpoints/Conclusions

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
  • 15.1.2 Data Source
• 15.2 Disclaimer

This report focuses on the global Gene Therapy for CNS Disorders status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Gene Therapy for CNS Disorders development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
Gilead (Kite Pharma)
Amgen (BioVex)
Novartis
Roche (Spark Therapeutics)
Bluebird Bio
...

Market segment by Type, the product can be split into
Ex Vivo
In Vivo
Market segment by Application, split into
Hospitals
Clinics
Others

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Gene Therapy for CNS Disorders status, future forecast, growth opportunity, key market and key players.
To present the Gene Therapy for CNS Disorders development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Gene Therapy for CNS Disorders are as follows:
History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.